The amount of autologous and allogeneic hematopoietic stem cell transplants for hematologic disorders has increased over time in tandem with longer survival, according to results of an observational study. Researchers observed improvements across all racial and ethnic groups but found that disparities related to treatment outcomes still exist.
Study estimates COVID-19 hospitalization and mortality rates in the US during the pre-vaccination period, revealing significant age and racial disparities in outcomes.
Despite the increased survival rates in all 4 evaluated racial groups, both adult and pediatric non-Hispanic African American patients continued to have worse outcomes.
Survival rates were similar between non-Hispanic African American and non-Hispanic White patients who received treatment, indicating a need to address barriers to multiple myeloma treatment and racial disparities.
The Center on Health Equity and Access delivers current updates, highlights breakthroughs in research, and ongoing endeavors committed to addressing healthcare inequalities and improving universal access to exceptional health care.